Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2017.23.3-b.s3
Abstract: DISCLOSURES Maher has received grants, consulting fees, and speaker fees from GlaxoSmithKline and UCB and grants from Novartis. He has also received consulting fees and speaker fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla,… read more here.
Keywords: idiopathic pulmonary; boehringer ingelheim; pulmonary fibrosis; survival idiopathic ... See more keywords